Skip to content

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01077258
Enrollment
4208
Registered
2010-03-01
Start date
2004-04-30
Completion date
2013-02-28
Last updated
2014-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Safety, Long-term observation, Routine Clinical Setting, Rheumatoid Arthritis, Effectiveness

Brief summary

Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over 2 years.

Detailed description

Patients with rheumatoid arthritis who started treatment with adalimumab in a normal clinical setting according to the product label were documented. The follow-up observation period was for 2 years and focused on safety information and maintenance of efficacy during a normal clinical setting. Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.

Interventions

None listed

Sponsors

AbbVie (prior sponsor, Abbott)
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Moderate to severe active rheumatoid arthritis in adults with insufficient response to disease-modifying antirheumatic drugs, including methotrexate * Moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before. In case of incompatibility with methotrexate, Humira can be used as monotherapy

Exclusion criteria

* Hypersensitivity against the drug or one of the other ingredients * Active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) * Moderate to severe cardiac insufficiency

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Disease Activity Score (DAS) 28Baseline and Months 3, 6, 9, 12, 18, and 24The Disease Activity Score 28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 score. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Percentage of Participants in DAS28 RemissionMonths 3, 6, 9, 12, 18, and 24Clinical remission is defined as a disease activity score (DAS) 28 score of \< 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity.

Secondary

MeasureTime frameDescription
Erythrocyte Sedimentation Rate (ESR) Over TimeBaseline and Months 3, 6, 9, 12, 18, and 24Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.
C-Reactive Protein (CRP) Levels Over TimeBaseline and Months 3, 6, 9, 12, 18, and 24C-Reactive Protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age.
Tender Joint Count (TJC) Over TimeBaseline and Months 3, 6, 9, 12, 18, and 24Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.
Swollen Joint Count (SJC) Over TimeBaseline and Months 3, 6, 9, 12, 18, and 24Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.
Hannover Functional Questionnaire (FFbH) Over TimeBaseline and Months 3, 6, 9, 12, 18, and 24A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score. The FFbH was calculated from this patient score by the following formula: FFbH = (patient score x 100) ÷ 2 (number of valid responses). The resulting FFbH score reflects the degree of remaining functional capacity where 0 indicates maximal impairment and 100 indicates maximal functional capacity.
Patients Global Assessment of Disease Activity Over TimeBaseline and Months 3, 6, 9, 12, 18 and 24Participants indicated their global assessment of disease activity over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.
Percentage of Participants With a Significant Therapeutic ResponseBaseline and Months 3, 6, 9, 12, 18, and 24Significant therapeutic response was determined by DAS28 critical difference (Dcrit). A Dcrit response is a statistically determined value that exceeds the threshold of random fluctuation and signifies a positive individual response during treatment. A DAS28-Dcrit individual therapeutic response is defined as a decrease (improvement) in DAS28 from Baseline of ≥ 1.8. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity.
Participants Assessment of Pain Over TimeBaseline and Months 3, 6, 9, 12, 18, and 24Participants indicated their level of pain over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.
Percentage of Participants With Impairment in Daily ActivitiesBaseline and Months 3, 6, 9, 18, and 24Participants were asked to report how many days of impairment in daily activities they had experienced in the last 4 weeks.
Number of Days Missed From Work Due to Rheumatoid ArthritisBaseline and Months 6, 12, 18, and 24Participants reported the number of days they had missed from work in the prior 6 months. The Baseline measurement includes data for the prior 12 months.
Percentage of Participants With In-patient HospitalizationMonth 6, 12, 18, and 24The percentage of participants with in-patient hospitalization in the prior 6 months. Baseline data includes in-patient hospitalizations that occurred within the prior 12 months.
Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationBaseline and Months 3, 6, 9, 12, 18, and 24
Participants Assessment of Fatigue Over TimeBaseline and Month 3, 6, 9, 12, 18, and 24Participants indicated their level of fatigue over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.
Percentage of Participants With Low, Moderate and High Disease ActivityBaseline and Months 3, 6, 9, 12, 18, and 24The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Low disease activity is defined as a DAS28 score ≤ 3.2; Moderate disease activity as a DAS28 \>3.2 to ≤5.1; High disease activity as a DAS28 \>5.1.

Countries

Germany

Participant flow

Participants by arm

ArmCount
Rheumatoid Arthritis
Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months.
4,208
Total4,208

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse drug reaction218
Overall StudyClinical remission37
Overall StudyLack of Efficacy663
Overall StudyLost to Follow-up1,390
Overall StudyOther reasons260

Baseline characteristics

CharacteristicRheumatoid Arthritis
Age, Continuous54.6 years
STANDARD_DEVIATION 13.2
Gender
Female
3199 participants
Gender
Male
958 participants
Region of Enrollment
Germany
4208 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 4,208
serious
Total, serious adverse events
245 / 4,208

Outcome results

Primary

Change From Baseline in Disease Activity Score (DAS) 28

The Disease Activity Score 28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 score. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set (FAS). Participants with inadequate data or who met other exclusion criteria were not included in the FAS. n indicates the number of participants with available data at each time point.

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisChange From Baseline in Disease Activity Score (DAS) 28Month 3 (n=2620)-1.5 units on a scaleStandard Deviation 1.3
Rheumatoid ArthritisChange From Baseline in Disease Activity Score (DAS) 28Month 6 (n=2243-1.8 units on a scaleStandard Deviation 1.4
Rheumatoid ArthritisChange From Baseline in Disease Activity Score (DAS) 28Month 9 (n=1877)-1.9 units on a scaleStandard Deviation 1.4
Rheumatoid ArthritisChange From Baseline in Disease Activity Score (DAS) 28Month 12 (n=1776)-2.0 units on a scaleStandard Deviation 1.4
Rheumatoid ArthritisChange From Baseline in Disease Activity Score (DAS) 28Month 18 (n=1519)-2.1 units on a scaleStandard Deviation 1.4
Rheumatoid ArthritisChange From Baseline in Disease Activity Score (DAS) 28Month 24 (n=1248)-2.2 units on a scaleStandard Deviation 1.4
Primary

Percentage of Participants in DAS28 Remission

Clinical remission is defined as a disease activity score (DAS) 28 score of \< 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity.

Time frame: Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (NUMBER)
Rheumatoid ArthritisPercentage of Participants in DAS28 RemissionMonth 3 (n=2620)18.1 percentage of participants
Rheumatoid ArthritisPercentage of Participants in DAS28 RemissionMonth 6 (n=2243)22.0 percentage of participants
Rheumatoid ArthritisPercentage of Participants in DAS28 RemissionMonth 12 (n=1776)27.2 percentage of participants
Rheumatoid ArthritisPercentage of Participants in DAS28 RemissionMonth 18 (n=1519)29.8 percentage of participants
Rheumatoid ArthritisPercentage of Participants in DAS28 RemissionMonth 24 (n=1248)34.6 percentage of participants
Rheumatoid ArthritisPercentage of Participants in DAS28 RemissionMonth 9 (n=1877)26.1 percentage of participants
Secondary

C-Reactive Protein (CRP) Levels Over Time

C-Reactive Protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 0 (n=2899)20.0 mg/LStandard Deviation 36.6
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 3 (n=2677)11.9 mg/LStandard Deviation 31.9
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 6 (n=2289)9.2 mg/LStandard Deviation 19.5
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 9 (n=1936)8.1 mg/LStandard Deviation 15.8
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 12 (n=1813)8.0 mg/LStandard Deviation 17.7
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 18 (n=1537)6.6 mg/LStandard Deviation 11.9
Rheumatoid ArthritisC-Reactive Protein (CRP) Levels Over TimeMonth 24 (n=1297)5.7 mg/LStandard Deviation 10.9
Secondary

Erythrocyte Sedimentation Rate (ESR) Over Time

Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 0 (n=2900)32.1 mm/hourStandard Deviation 22
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 3 (n=2684)23.2 mm/hourStandard Deviation 20.2
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 6 (n=2259)22.1 mm/hourStandard Deviation 19.1
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 9 (n=1910)21.6 mm/hourStandard Deviation 18.2
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 12 (n=1805)21.4 mm/hourStandard Deviation 17.9
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 18 (n=1515)21.0 mm/hourStandard Deviation 17.5
Rheumatoid ArthritisErythrocyte Sedimentation Rate (ESR) Over TimeMonth 24 (n=1263)21.2 mm/hourStandard Deviation 18.7
Secondary

Hannover Functional Questionnaire (FFbH) Over Time

A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score. The FFbH was calculated from this patient score by the following formula: FFbH = (patient score x 100) ÷ 2 (number of valid responses). The resulting FFbH score reflects the degree of remaining functional capacity where 0 indicates maximal impairment and 100 indicates maximal functional capacity.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 0 (n=2938)61.9 units on a scaleStandard Deviation 22.4
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 3 (n=2755)68.4 units on a scaleStandard Deviation 22.5
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 6 (n=2369)70.4 units on a scaleStandard Deviation 22.2
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 9 (n=1997)71.3 units on a scaleStandard Deviation 22.5
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 12 (n=1882)71.9 units on a scaleStandard Deviation 22.4
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 18 (n=1623)72.4 units on a scaleStandard Deviation 22.5
Rheumatoid ArthritisHannover Functional Questionnaire (FFbH) Over TimeMonth 24 (n=1341)72.7 units on a scaleStandard Deviation 22.7
Secondary

Number of Days Missed From Work Due to Rheumatoid Arthritis

Participants reported the number of days they had missed from work in the prior 6 months. The Baseline measurement includes data for the prior 12 months.

Time frame: Baseline and Months 6, 12, 18, and 24

Population: Full analysis set participants who were employed and with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisNumber of Days Missed From Work Due to Rheumatoid ArthritisMonth 0 (n=1168)20.6 daysStandard Deviation 52.4
Rheumatoid ArthritisNumber of Days Missed From Work Due to Rheumatoid ArthritisMonth 6 (n=938)9.9 daysStandard Deviation 33.2
Rheumatoid ArthritisNumber of Days Missed From Work Due to Rheumatoid ArthritisMonth 12 (n=728)4.4 daysStandard Deviation 21.3
Rheumatoid ArthritisNumber of Days Missed From Work Due to Rheumatoid ArthritisMonth 18 (n=604)5.2 daysStandard Deviation 27.1
Rheumatoid ArthritisNumber of Days Missed From Work Due to Rheumatoid ArthritisMonth 24 (n=507)3.8 daysStandard Deviation 17.9
Secondary

Participants Assessment of Fatigue Over Time

Participants indicated their level of fatigue over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.

Time frame: Baseline and Month 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 0 (n=2940)5.8 cmStandard Deviation 2.5
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 3 (n=2727)4.5 cmStandard Deviation 2.7
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 6 (n=2351)4.2 cmStandard Deviation 2.6
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 9 (n=1976)4.0 cmStandard Deviation 2.6
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 12 (n=1864)4.0 cmStandard Deviation 2.6
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 18 (n=1608)3.9 cmStandard Deviation 2.6
Rheumatoid ArthritisParticipants Assessment of Fatigue Over TimeMonth 24 (n=1335)3.7 cmStandard Deviation 2.6
Secondary

Participants Assessment of Pain Over Time

Participants indicated their level of pain over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 0 (n=2942)6.4 cmStandard Deviation 2.1
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 3 (n=2732)4.5 cmStandard Deviation 2.4
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 6 (n=2356)4.2 cmStandard Deviation 2.4
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 9 (n=1973)4.1 cmStandard Deviation 2.4
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 12 (n=1866)3.9 cmStandard Deviation 2.4
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 18 (n=1609)3.9 cmStandard Deviation 2.4
Rheumatoid ArthritisParticipants Assessment of Pain Over TimeMonth 24 (n=1339)3.7 cmStandard Deviation 2.4
Secondary

Patients Global Assessment of Disease Activity Over Time

Participants indicated their global assessment of disease activity over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.

Time frame: Baseline and Months 3, 6, 9, 12, 18 and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 0 (n=2950)6.3 cmStandard Deviation 1.9
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 3 (n=2731)4.7 cmStandard Deviation 2.2
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 6 (n=2353)4.4 cmStandard Deviation 2.1
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 9 (n=1975)4.2 cmStandard Deviation 2.1
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 12 (n=1869)4.1 cmStandard Deviation 2.1
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 18 (n=1609)4.0 cmStandard Deviation 2.1
Rheumatoid ArthritisPatients Global Assessment of Disease Activity Over TimeMonth 24 (n=1339)3.8 cmStandard Deviation 2.1
Secondary

Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (NUMBER)
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide22.1 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug46.1 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine2.5 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug4.5 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors12.4 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics21.8 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids80.9 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine6.2 percentage of participants
Rheumatoid ArthritisPercentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate54.0 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics15.4 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug2.8 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids73.4 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine3.7 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors10.4 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine2.0 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate52.3 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug36.9 percentage of participants
Month 3Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide18.0 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug34.2 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug2.5 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate53.2 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine3.6 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics14.9 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors10.2 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide15.9 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine1.6 percentage of participants
Month 6Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids69.1 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics14.0 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate53.1 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine3.2 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine1.2 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide15.3 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug2.3 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug33.9 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors9.6 percentage of participants
Month 9Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids65.7 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors9.2 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide15.0 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate53.2 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine1.2 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug2.0 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids62.1 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug32.7 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics12.9 percentage of participants
Month 12Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine3.5 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine3.3 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide14.1 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors9.6 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate52.9 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug31.7 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine1.3 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug2.2 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids58.8 percentage of participants
Month 18Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics11.7 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSulfasalazine2.8 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationAnalgesics12.0 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationHydroxychloroquine/Chloroquine1.4 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationNon-steroidal anti-inflammatory drug30.5 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationLeflunomide12.7 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationCyclo-oxygenase 2 (COX-2) Inhibitors9.7 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationMethotrexate51.0 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationSystemic glucocorticoids57.4 percentage of participants
Month 24Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory MedicationOther disease-modifying antirheumatic drug2.1 percentage of participants
Secondary

Percentage of Participants With a Significant Therapeutic Response

Significant therapeutic response was determined by DAS28 critical difference (Dcrit). A Dcrit response is a statistically determined value that exceeds the threshold of random fluctuation and signifies a positive individual response during treatment. A DAS28-Dcrit individual therapeutic response is defined as a decrease (improvement) in DAS28 from Baseline of ≥ 1.8. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (NUMBER)
Rheumatoid ArthritisPercentage of Participants With a Significant Therapeutic ResponseMonth 3 (n=2620)38.9 percentage of participants
Rheumatoid ArthritisPercentage of Participants With a Significant Therapeutic ResponseMonth 6 (n=2243)49.1 percentage of participants
Rheumatoid ArthritisPercentage of Participants With a Significant Therapeutic ResponseMonth 9 (n=1877)54.7 percentage of participants
Rheumatoid ArthritisPercentage of Participants With a Significant Therapeutic ResponseMonth 12 (n=1776)56.3 percentage of participants
Rheumatoid ArthritisPercentage of Participants With a Significant Therapeutic ResponseMonth 18 (n=1519)60.1 percentage of participants
Rheumatoid ArthritisPercentage of Participants With a Significant Therapeutic ResponseMonth 24 (n=1248)61.9 percentage of participants
Secondary

Percentage of Participants With Impairment in Daily Activities

Participants were asked to report how many days of impairment in daily activities they had experienced in the last 4 weeks.

Time frame: Baseline and Months 3, 6, 9, 18, and 24

Population: Full analysis set with available data at each time point

ArmMeasureGroupValue (NUMBER)
Rheumatoid ArthritisPercentage of Participants With Impairment in Daily ActivitiesNo days of impairment19.7 percentage of participants
Rheumatoid ArthritisPercentage of Participants With Impairment in Daily ActivitiesLess than 7 days of impairment28.5 percentage of participants
Rheumatoid ArthritisPercentage of Participants With Impairment in Daily Activities7 to 14 days of impairment28.8 percentage of participants
Rheumatoid ArthritisPercentage of Participants With Impairment in Daily ActivitiesMore than 14 days of impairment23.0 percentage of participants
Month 3Percentage of Participants With Impairment in Daily Activities7 to 14 days of impairment16.1 percentage of participants
Month 3Percentage of Participants With Impairment in Daily ActivitiesLess than 7 days of impairment36.3 percentage of participants
Month 3Percentage of Participants With Impairment in Daily ActivitiesNo days of impairment35.8 percentage of participants
Month 3Percentage of Participants With Impairment in Daily ActivitiesMore than 14 days of impairment11.7 percentage of participants
Month 6Percentage of Participants With Impairment in Daily ActivitiesMore than 14 days of impairment9.4 percentage of participants
Month 6Percentage of Participants With Impairment in Daily Activities7 to 14 days of impairment14.9 percentage of participants
Month 6Percentage of Participants With Impairment in Daily ActivitiesLess than 7 days of impairment35.5 percentage of participants
Month 6Percentage of Participants With Impairment in Daily ActivitiesNo days of impairment40.3 percentage of participants
Month 9Percentage of Participants With Impairment in Daily ActivitiesNo days of impairment45.7 percentage of participants
Month 9Percentage of Participants With Impairment in Daily ActivitiesMore than 14 days of impairment7.8 percentage of participants
Month 9Percentage of Participants With Impairment in Daily ActivitiesLess than 7 days of impairment33.3 percentage of participants
Month 9Percentage of Participants With Impairment in Daily Activities7 to 14 days of impairment13.2 percentage of participants
Month 12Percentage of Participants With Impairment in Daily Activities7 to 14 days of impairment12.0 percentage of participants
Month 12Percentage of Participants With Impairment in Daily ActivitiesMore than 14 days of impairment6.7 percentage of participants
Month 12Percentage of Participants With Impairment in Daily ActivitiesLess than 7 days of impairment30.0 percentage of participants
Month 12Percentage of Participants With Impairment in Daily ActivitiesNo days of impairment51.4 percentage of participants
Month 18Percentage of Participants With Impairment in Daily ActivitiesLess than 7 days of impairment30.4 percentage of participants
Month 18Percentage of Participants With Impairment in Daily Activities7 to 14 days of impairment10.8 percentage of participants
Month 18Percentage of Participants With Impairment in Daily ActivitiesMore than 14 days of impairment6.7 percentage of participants
Month 18Percentage of Participants With Impairment in Daily ActivitiesNo days of impairment52.1 percentage of participants
Secondary

Percentage of Participants With In-patient Hospitalization

The percentage of participants with in-patient hospitalization in the prior 6 months. Baseline data includes in-patient hospitalizations that occurred within the prior 12 months.

Time frame: Month 6, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (NUMBER)
Rheumatoid ArthritisPercentage of Participants With In-patient HospitalizationBaseline (n=2893)21.6 percentage of participants
Rheumatoid ArthritisPercentage of Participants With In-patient HospitalizationMonth 6 (n=2293)7.2 percentage of participants
Rheumatoid ArthritisPercentage of Participants With In-patient HospitalizationMonth 12 (n=1844)5.8 percentage of participants
Rheumatoid ArthritisPercentage of Participants With In-patient HospitalizationMonth 18 (n=1584)5.4 percentage of participants
Rheumatoid ArthritisPercentage of Participants With In-patient HospitalizationMonth 24 (n=1320)3.6 percentage of participants
Secondary

Percentage of Participants With Low, Moderate and High Disease Activity

The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Low disease activity is defined as a DAS28 score ≤ 3.2; Moderate disease activity as a DAS28 \>3.2 to ≤5.1; High disease activity as a DAS28 \>5.1.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point

ArmMeasureGroupValue (NUMBER)
Rheumatoid ArthritisPercentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity64.3 percentage of participants
Rheumatoid ArthritisPercentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity35.7 percentage of participants
Rheumatoid ArthritisPercentage of Participants With Low, Moderate and High Disease ActivityLow disease activity0.0 percentage of participants
Month 3Percentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity45.9 percentage of participants
Month 3Percentage of Participants With Low, Moderate and High Disease ActivityLow disease activity30.2 percentage of participants
Month 3Percentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity23.9 percentage of participants
Month 6Percentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity17.9 percentage of participants
Month 6Percentage of Participants With Low, Moderate and High Disease ActivityLow disease activity36.5 percentage of participants
Month 6Percentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity45.6 percentage of participants
Month 9Percentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity43.9 percentage of participants
Month 9Percentage of Participants With Low, Moderate and High Disease ActivityLow disease activity41.8 percentage of participants
Month 9Percentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity14.3 percentage of participants
Month 12Percentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity43.1 percentage of participants
Month 12Percentage of Participants With Low, Moderate and High Disease ActivityLow disease activity43.7 percentage of participants
Month 12Percentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity13.2 percentage of participants
Month 18Percentage of Participants With Low, Moderate and High Disease ActivityLow disease activity46.7 percentage of participants
Month 18Percentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity11.6 percentage of participants
Month 18Percentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity41.7 percentage of participants
Month 24Percentage of Participants With Low, Moderate and High Disease ActivityHigh disease activity10.9 percentage of participants
Month 24Percentage of Participants With Low, Moderate and High Disease ActivityModerate disease ctivity37.7 percentage of participants
Month 24Percentage of Participants With Low, Moderate and High Disease ActivityLow disease activity51.4 percentage of participants
Secondary

Swollen Joint Count (SJC) Over Time

Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 0 (n=2950)7.7 swollen jointsStandard Deviation 5.6
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 3 (n=2768)3.7 swollen jointsStandard Deviation 4.6
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 6 (n=2375)3.0 swollen jointsStandard Deviation 4.1
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 9 (n=2003)2.6 swollen jointsStandard Deviation 3.8
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 12 (n=1868)2.4 swollen jointsStandard Deviation 3.7
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 24 (n=1326)2.0 swollen jointsStandard Deviation 3.4
Rheumatoid ArthritisSwollen Joint Count (SJC) Over TimeMonth 18 (n=1609)2.1 swollen jointsStandard Deviation 3.4
Secondary

Tender Joint Count (TJC) Over Time

Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.

Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24

Population: Full analysis set with available data at each time point (indicated by n)

ArmMeasureGroupValue (MEAN)Dispersion
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 0 (n=2950)10.6 tender jointsStandard Deviation 6.7
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 3 (n=2778)5.4 tender jointsStandard Deviation 6.1
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 6 (n=2393)4.3 tender jointsStandard Deviation 5.4
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 9 (n=2010)3.9 tender jointsStandard Deviation 5.4
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 12 (n=1886)3.6 tender jointsStandard Deviation 5
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 18 (n=1621)3.4 tender jointsStandard Deviation 4.9
Rheumatoid ArthritisTender Joint Count (TJC) Over TimeMonth 24 (n=1339)3.1 tender jointsStandard Deviation 4.5

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026